


Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claim 1. (currently amended) A method ~~of treating or preventing~~ according to claim 5, wherein the disease is Alzheimer's disease. ~~in a subject in need of such treatment comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.~~



~~wherein R₁ is~~

- ~~a) Cbz-Val;~~
- ~~b) Cbz-Ala;~~
- ~~c) Cbz; or~~
- ~~d) Boc;~~

~~R₂ is~~

- ~~a) H;~~
- ~~b) C₁₋₆ alkyl, alkenyl, or alkynyl; or~~

~~e) cycloalkyl; and~~

~~X is~~

~~— a) C=O; or~~

~~b) (CH₂)OH.~~


Claim 2. (original) A method of treating Alzheimer's disease in a subject in need of such treatment comprising administering to the subject a compound disclosed in claim 1, or a pharmaceutically acceptable salt thereof.

Claim 3. (original) A method of treating Alzheimer's disease by modulating the activity of beta amyloid converting enzyme, comprising administering to a subject in need of such treatment a compound disclosed in claim 1, or a pharmaceutically acceptable salt thereof.

Claim 4. (original) The method according to claim 1, further comprising the administration of a P-gp inhibitor, or a pharmaceutically acceptable salt thereof.

Claim 5. (original) A method of treating a subject who has, or in preventing a subject from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's

disease, for treating subjects with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment which includes administration of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof:



wherein R₁ is

- a) Cbz-Val;
- b) Cbz-Ala;

c) Cbz; or

d) Boc;

R₂ is

a) H;

b) C₁₋₆ alkyl, alkenyl, or alkynyl; or



c) cycloalkyl; and





X is




a) C=O; or

b) (CH₂)OH.

Claim 6. (currently amended) The method according to claim 5 ~~any of claim 1-5~~ wherein the compound of formula (I) is selected from the group consisting of:








and pharmaceutically acceptable salts thereof or
~~pharmaceutically acceptable salts thereof.~~

Claims 7-8. (cancelled)

Claim 9. (original) A method for inhibiting beta-secretase activity, comprising contacting an effective amount for inhibition of a compound of formula (I):



wherein R_1 is

- a) Cbz-Val;
- b) Cbz-Ala;
- c) Cbz; or
- d) Boc;

R_2 is


- a) H;
- b) C_{1-6} alkyl, alkenyl, or alkynyl; or
- c) cycloalkyl; and

X is

- a) $C=O$; or
- b) $(CH_2)OH$.

Claim 10. (cancelled)

Claim 11. (original) A method for inhibiting production of amyloid beta peptide (A beta) in a cell, comprising administering to said cell an effective inhibitory amount of a compound of formula (I):



wherein R₁ is

- a) Cbz-Val;
- b) Cbz-Ala;
- c) Cbz; or
- d) Boc;

R₂ is

- a) H;
- b) C₁₋₆ alkyl, alkenyl, or alkynyl; or
- c) cycloalkyl; and

X is

- a) C=O; or
- b) (CH₂)OH.

Claim 12. (original) The method of claim 11, wherein the cell is an animal cell.

Claim 13. (original) The method of claim 12, wherein the animal cell is a mammalian cell.

Claim 14. (original) The method of claim 13, wherein the mammalian cell is human.

Claims 15-19. (cancelled)

Claim 20. (currently amended) A method of treatment according to claim 5 ~~any of claims 1-5~~, further comprising administration of one or more therapeutic agents selected from the group consisting of an antioxidant, an anti-inflammatory, a gamma secretase inhibitor, a neurotrophic agent, an acetyl cholinesterase inhibitor, a statin, an A beta peptide, and an anti-A beta peptide.

Claims 21-22. (cancelled)